Strive, Inc., the corporate treasury firm founded by Vivek Ramaswamy, said it had accumulated 13,628 bitcoin as of March 17, 2026. That total placed the company among the top 10 corporate bitcoin holders globally. The pace of accumulation is notable because it happened in roughly the first six months after Strive’s September 2025 public listing, showing how aggressively the firm moved to build a bitcoin-heavy balance sheet.
The headline number came with a major trade-off. For the period ended December 31, 2025, Strive reported a GAAP net loss of $393.6 million. In practical terms, the company was pursuing rapid bitcoin accumulation while absorbing the accounting effects of market volatility, acquisition-related adjustments, and financing activity. That makes Strive a useful case study in how public companies can expand digital asset reserves quickly, yet still report deeply negative earnings under conventional accounting rules.
Strive’s bitcoin stockpile came from several channels rather than one large buy program. According to the company, initial private investment proceeds and stock exchange activity contributed 5,886 bitcoin. The acquisition of Semler Scientific, Inc. added approximately 5,048 bitcoin. Another 2,694 bitcoin came from capital markets activity, including public offerings of Strive’s Variable Rate Series A Perpetual Preferred Stock, or SATA, follow-on offerings, and at-the-market issuances.
The Semler acquisition mattered for more than corporate expansion. Semler had already built its own digital asset reserve before the deal, so the acquisition immediately boosted Strive’s bitcoin treasury. This means Strive’s position was not purely the result of open-market accumulation. It also reflects balance-sheet consolidation through M&A and continued use of capital markets instruments to extend its bitcoin strategy beyond the initial listing period.
Where Strive’s losses came from
Strive’s financial results illustrate the tension between aggressive treasury accumulation and the way public markets account for volatile assets. A significant share of the company’s GAAP net loss was tied to non-cash items rather than immediate operating cash outflows. The largest single component was $194.5 million in unrealized losses on bitcoin holdings, which represented nearly 50% of the total GAAP deficit.
Additional pressure came from the Semler transaction. Strive recorded $140.8 million in impairment of goodwill and intangible assets related to the acquisition, while transaction-related expenses added another $12.4 million. After adjusting for these items, the company said its non-GAAP loss attributable to common shareholders narrowed to $208.2 million, or $4.73 per diluted share. That gap between GAAP and adjusted figures is central to understanding the company’s narrative.
For bitcoin treasury companies, this distinction matters. A firm can continue holding its bitcoin and still post large accounting losses if market prices move against the carrying value assumptions used in financial reporting. In other words, the income statement may look weak even when the company has not realized those losses through sales. Strive’s numbers are a direct example of how a bitcoin-centric treasury strategy can distort headline profitability.
The role of “Bitcoin Yield” in Strive’s narrative
To frame performance beyond standard earnings metrics, management introduced a proprietary measure called Bitcoin Yield. The metric is intended to capture the performance of Strive’s digital asset portfolio. On that basis, the company reported a 22.2% yield in Q4 2025 and a 13.8% quarter-to-date yield through mid-March 2026.
Strive translated those percentages into bitcoin-denominated gains, saying they were equivalent to increases of 1,305 bitcoin and 1,050 bitcoin, respectively. In dollar terms, those gains amounted to approximately $114.3 million and $78.2 million over the same periods. Management’s use of this metric suggests it wants investors to evaluate the company not only through GAAP earnings, but through the efficiency with which it converts financing capacity and capital market activity into additional bitcoin exposure.
Still, a proprietary metric has limitations. Bitcoin Yield may help explain how management measures strategic execution, but it does not replace traditional analysis of dilution, funding costs, preferred stock obligations, or market risk. Investors can treat it as a supplemental lens, not as a full substitute for standard accounting or balance-sheet review.
How Strive financed its bitcoin strategy
Strive’s accumulation plan was funded largely through structured finance products. In November 2025, the company raised $148.4 million in net proceeds from its initial offering of SATA preferred stock, priced at $80 per share. This was one of the core building blocks of its treasury strategy and a key example of the structured financing model management has emphasized.
Then, in January 2026, Strive completed a follow-on offering that generated another $109.2 million at $90 per share. The proceeds were not used solely for new bitcoin purchases. Part of the money went toward retiring a $20 million loan from Coinbase Credit Inc. that Strive had assumed as part of the Semler acquisition. Another portion was used to exchange preferred shares for $90 million of Semler’s convertible debt.
The company also referenced other capital markets activity such as additional follow-on offerings and at-the-market issuances. The broader strategy is clear: use liquid and scalable financing tools to support bitcoin accumulation while also reshaping liabilities and improving capital structure. This approach can accelerate treasury growth, but it also ties the company more closely to market access, investor demand, and the pricing environment for its securities.
The Semler deal also left Strive with an operating healthcare business
Semler Scientific was valuable to Strive not only because of its bitcoin holdings. The acquisition also included an operating business that is now housed under a wholly owned subsidiary called Clinivanta, focused on preventative healthcare. That means Strive is not a pure bitcoin treasury vehicle. It also owns a business unit with operating activities outside digital assets.
To lead that segment, the company appointed Michelle Fox, formerly Chief Medical Officer of Teleflex, as CEO of Clinivanta in February 2026. The move signals that Strive does not intend to simply warehouse the acquired operating business. Instead, it appears to be developing that healthcare platform while continuing to prioritize bitcoin accumulation.
This creates a more complex corporate profile. On one side, Strive looks like a structured-finance-driven bitcoin treasury company. On the other, it still has exposure to an operating healthcare business that could contribute diversification or strategic optionality. How investors value that mix will likely depend on bitcoin market conditions, financing efficiency, and whether Clinivanta can generate durable operating results.
How management framed the first six months
Chairman and CEO Matthew Cole described the results as validation of Strive’s structured finance approach. In his view, the company’s most important achievement during its first six months as a public company was establishing a solid foundation as a structured finance company focused intensely on digital credit. That language is important because it shows how management wants the market to understand the business model.
Cole also argued that the SATA instrument offers a liquid and scalable solution for investors seeking double-digit yield with minimal volatility. In that sense, Strive is presenting SATA not just as a funding source for its bitcoin strategy, but as a product aligned with investor demand. The broader goal appears to be balancing bitcoin accumulation with wider financial operations, rather than relying on a single narrative of simply buying and holding BTC.
As of March 17, 2026, Strive reported $83.7 million in cash and $50.4 million in fair value of STRC preferred stock. Those figures indicate the company still had a liquidity buffer in place. Whether the model remains sustainable will depend on future access to capital, the volatility of bitcoin prices, and the company’s ability to integrate Semler while developing Clinivanta alongside its treasury strategy.